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Safety, tolerability and efficacy of volixibat in adults with non-alcoholic steatohepatitis: 
24-week interim analysis results from a randomized, double-blind, phase 2 study
Histologic assessments at week 48 (n = 43)Interim analysis at week 24 (n = 80)
197 adults with ≥5% steatosis and biopsy-confirmed NASH 
received volixibat (5, 10 or 20 mg) or placebo for 48 weeks
C4 (bile acid synthesis)
+38.5 ng/mL
Total cholesterol
–14.5 mg/dL
LDL cholesterol 
–16.1 mg/dL
Evidence of adequate 
target engagement
De novo production of bile 
acids from cholesterol
Volixibat 5, 10 or 20 mg
No effect of volixibat on MRI-PDFF or serum ALT levels
ALT, alanine aminotransferase; C4, 7-alpha-hydroxy-4-cholesten-3-one; LDL, low-density lipoprotein; MRI-PDFF, magnetic resonance imaging-proton density fat fraction; NASH, non-alcoholic 
steatohepatitis; NAS, non-alcoholic fatty liver disease activity score
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Abstract 
Background & Aims:  
Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), 
hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake 
and stimulating hepatic bile acid production. 
Methods:  
Adults with ≥5% steatosis and NASH without cirrhosis (N = 197) were randomized to receive 
double-blind volixibat 5, 10 or 20 mg or placebo once daily for 48 weeks. A predefined 
interim analysis (n = 80) at week 24 had endpoints of ≥5% reduction in magnetic resonance 
imaging-proton density fat fraction and ≥20% reduction in serum alanine aminotransferase 
levels. The primary endpoint was ≥2-point reduction in non-alcoholic fatty liver disease 
activity score without worsening fibrosis at week 48.  
Results: 
Volixibat did not meet either interim endpoint; the study was terminated owing to lack of 
efficacy. In participants receiving any volixibat dose, mean serum 7-alpha-hydroxy-4-
cholesten-3-one (C4; a biomarker of bile acid synthesis) increased from baseline to week 24 
(+38.5 ng/mL [standard deviation (SD) 53.18]), with concomitant decreases in serum total 
cholesterol (–14.5 mg/dL [SD 28.32]) and low-density lipoprotein cholesterol (–16.1 mg/dL 
[SD 25.31]). These changes were generally dose-dependent. In the liver histology analysis, 
a greater proportion of participants receiving placebo (38.5%, n = 5/13) than volixibat 
(30.0%, n = 9/30) met the primary endpoint. Treatment-emergent adverse events (TEAEs) 
were mainly mild or moderate. No serious TEAEs were related to volixibat. Diarrhoea was 
the most common TEAE overall and the most common TEAE leading to discontinuation. 
Conclusions: 
Increased serum C4 and decreased serum cholesterol levels provide evidence of target 
engagement. However, there was no therapeutic benefit of ASBT inhibition with volixibat on 
the liver in adults with NASH (ClinicalTrials.gov identifier: NCT02787304). 
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Lay summary: 
A medicine called volixibat has previously been shown to reduce cholesterol levels in the 
blood. This study investigated whether volixibat could reduce the amount of fat in the liver 
and reduce liver injury in adults with an advanced form of non-alcoholic fatty liver disease. 
Volixibat did not reduce the amount of fat in the liver, nor did it have any other beneficial 
effect on liver injury. Participants in the study generally tolerated the side effects of volixibat 
and, as in previous studies, the main side effect was diarrhoea. These results show that 
volixibat is not an effective treatment for people with fatty liver disease. 
Highlights 
• Volixibat decreased serum C4 (bile acid synthesis biomarker) and cholesterol. 
• These results suggest adequate target engagement. 
• Volixibat had no therapeutic impact on steatosis or liver injury in NASH. 
• Treatment-emergent adverse events were mainly of mild or moderate grade. 
• No serious adverse events were attributed to volixibat.
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Introduction 
Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver 
disease (NAFLD), characterized by the hepatic accumulation of fat (steatosis), inflammation 
and hepatocellular injury (ballooning), with or without progressive fibrosis; it can lead to 
cirrhosis, liver failure and liver cancer.1-3 Large meta-analyses demonstrate that NASH 
progresses faster and is associated with greater liver-related and overall mortality than 
NAFLD.4,5 The prevalence of NASH is difficult to determine because it is often asymptomatic 
and because a definitive diagnosis requires a liver biopsy for histologic examination.1,6,7 An 
estimated 12.2% of middle-aged adults may have NASH in the USA, rising to 22% among 
those with diabetes and to 33% among those with obesity.7,8 In 2014, NASH surpassed 
chronic hepatitis C as the leading indication for liver transplantation in adults younger than 
50 years of age in the USA;9 in Europe, the proportion of liver transplants attributed to NASH 
increased from 1.2% in 2002 to 8.4% in 2016.10 
There is currently no marketed pharmacological treatment for NASH.11 Clinical practice 
guidelines for the management of NAFLD recommend behavioural change intended to 
reduce body weight through dietary restriction and physical activity.12 However, such 
interventions are often limited in their therapeutic effect owing to poor long-term adherence 
and considerable rates of weight regain.13,14 Therefore, there is a significant unmet need for 
an effective pharmacological treatment for patients with NASH. 
Abnormal cholesterol metabolism and accumulation of free cholesterol in the liver contribute 
directly to the pathogenesis of NASH15,16 because free cholesterol is toxic to hepatocytes, 
driving development of inflammation and fibrosis.17 Volixibat potassium (SHP626; formerly 
LUM002; hereafter referred to as volixibat) is a highly selective, minimally absorbed 
competitive inhibitor of the apical sodium-dependent bile acid transporter (ASBT). ASBT 
inhibition may represent a strategy for therapeutic intervention in patients with NASH, owing 
to its effects on cholesterol metabolism.18 ASBT is localized primarily on the luminal surface 
of ileal enterocytes and selectively reabsorbs bile acids (BAs) during enterohepatic 
recirculation.19,20 Inhibition of ASBT prevents reabsorption of BAs from the intestinal lumen, 
thereby increasing faecal BA excretion and reducing recirculation of BAs to the liver via the 
hepatic portal vein. Reduced recirculation of BAs stimulates de novo hepatic BA production 
from free cholesterol that is present in the liver and the bloodstream.21,22 Consistent with this 
mechanism of action, increases in serum levels of 7α-hydroxy-4-cholesten-3-one (7αC4, 
also known as C4; a biomarker of BA synthesis) and decreases in serum cholesterol levels 
are observed following administration of ASBT inhibitors, including volixibat.23-27 
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In the treatment of NASH, volixibat may reduce the pathogenic accumulation of cholesterol 
in the liver by reducing the levels of BAs returning to the liver via enterohepatic recirculation 
and by stimulating de novo production of BAs from free cholesterol in the liver and serum. 
This may have therapeutically beneficial anti-inflammatory, anti-steatotic and anti-fibrotic 
effects. Volixibat may also have positive metabolic effects because BAs act as signalling 
molecules that play a role in glucose metabolism pathways, including hepatic 
gluconeogenesis, glycogen synthesis and insulin sensitivity.28,29 In mice that were fed a high-
fat diet, administration of SC-435 (a surrogate of volixibat) significantly reduced hepatic 
concentrations of triglycerides, cholesteryl ester and total cholesterol to levels that were 
comparable to those of standard chow-fed mice.30 In addition, ASBT inhibition with SC-435 
or volixibat restored glucose tolerance and significantly decreased NAFLD activity score 
(NAS) and hepatocellular hypertrophy.30,31 SC-435 also blocked progression of sclerosing 
cholangitis and reduced hepatic fibrosis in mdr2–/– knockout mice.32 Phase 1 studies have 
demonstrated that volixibat is not metabolized, is minimally absorbed and is effective at 
reducing serum cholesterol in overweight and obese adults.18,26,27 The increases in faecal BA 
excretion and serum C4 levels observed in these phase 1 studies support the proposed 
mechanism of action of volixibat in patients with NASH. It is also important that volixibat was 
found to reduce fasting glucose levels significantly compared with placebo in patients with 
type 2 diabetes mellitus (T2DM)26 because there is a close association between NASH and 
T2DM.33-35 
Herein, we report the 24-week interim analysis of a 48-week, phase 2, proof-of-concept 
study of volixibat in adults with NASH. We also report the histologic analyses of participants 
who completed the study to week 48.   
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Methods 
Overview 
This was a randomized, double-blind, phase 2, placebo-controlled, parallel-group, proof-of-
concept, dose-finding study of volixibat in adults with NASH (ClinicalTrials.gov identifier: 
NCT02787304). All participants provided written informed consent. The study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by 
the independent ethics committee of each study site.  
Participants 
Eligible participants were 18–80 years of age, with at least 5% steatosis on centrally read 
magnetic resonance imaging-proton density fat fraction (MRI-PDFF) scans and with centrally 
read histologic confirmation of NASH without cirrhosis (fibrosis stage F0–F3).36 Participants 
were required to have a NAS of at least 4 points, with a score of at least 1 point in each NAS 
component (steatosis, lobular inflammation and hepatocyte ballooning). 
Patients were excluded if they had a history or presence of concomitant liver disease (e.g. 
decompensated liver disease, hepatocellular carcinoma) or any other current or recurrent 
disease that may affect the action or assessment of volixibat (including, but not limited to, 
uncontrolled inflammatory bowel disease, uncontrolled coeliac disease, gastric bypass or 
history of chronic diarrhoea). Participants were also ineligible if they had: type 1 diabetes 
mellitus or uncontrolled T2DM (defined as glycated haemoglobin levels of ≥9.5% in the 
60 days before enrolment); serum alanine aminotransferase (ALT) or aspartate 
aminotransferase levels at least seven times the upper limit of normal (ULN) at screening 
(normal range of ALT: 0–55 U/L); or a known history of alcohol or other substance abuse in 
the past year or at any time during the study. 
Design 
The study was conducted at 68 centres (53 in the USA, 6 in Canada and 9 in the UK) from 
October 2016 to July 2018. The predefined interim safety, tolerability and efficacy analysis 
was conducted in June 2018. Following the interim analysis, the study was terminated early 
owing to lack of efficacy. 
The study comprised a 10-week screening period, a 48-week treatment period and a 4-week 
follow-up. Participants were scheduled to attend the clinic at screening, at baseline, at weeks 
2, 4, 8, 12, 24, 36 and 48 of treatment, and at week 52 for follow-up. After screening, 
participants were randomized 1:1:1:1 to one of three doses of volixibat (5, 10 or 20 mg) or 
placebo, administered orally once daily in a double-blind fashion through the use of blinded 
blister packs. Doses were chosen based on phase 1 data.27 Participants were automatically 
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randomized to treatment groups based on an interactive response technology, stratified by 
the presence of T2DM and baseline NAS (divided into NAS = 4–5 or NAS = 6–8). 
Outcome measures 
The primary objective of the study was to examine the effect of volixibat compared with 
placebo on liver histology at week 48. Secondary objectives included the effect of volixibat 
on hepatic steatosis, assessed by MRI-PDFF, and serum ALT levels. 
Week 24 interim analysis 
The interim analysis of the safety, tolerability and efficacy of volixibat was prespecified to 
occur when 80 participants had received 24 weeks of treatment. In this interim analysis, 
clinically significant efficacy of volixibat was assessed based on predefined endpoints of 
absolute reduction from baseline to week 24 in steatosis of at least 5%, as assessed by 
MRI-PDFF, and relative reduction from baseline to week 24 in serum ALT levels of at least 
20%. BA synthesis was assessed via serum C4 concentration, as an exploratory 
pharmacodynamic outcome. Changes in serum glucose levels, serum lipid levels, body 
weight and waist-to-hip ratio were examined as additional interim endpoints.  
Week 48 analyses 
Week 48 analyses were conducted using data from participants who had reached this time 
point when the study was terminated. The prespecified primary endpoint was a reduction of 
at least 2 points in NAS, without worsening fibrosis, from baseline to week 48. A post hoc 
decision was made following early termination of the study to analyse the prespecified 
histologic outcomes in participants who had paired liver biopsies at screening and at week 
48. Secondary histologic endpoints were: decrease in fibrosis stage, irrespective of NAS; 
resolution of NASH (defined as absence of ballooning [score = 0] and absent or mild 
inflammation [score 0–1], with or without steatosis) without worsening fibrosis; and change in 
liver histology, as measured by the individual NAS components (ballooning, inflammation 
and steatosis).  
Changes in hepatic steatosis, as measured by MRI-PDFF, and serum ALT levels were 
assessed as additional secondary endpoints at week 48.  
Assessments 
Steatosis was assessed at screening and during weeks 24 and 48 clinic visits with a 
centrally read MRI-PDFF, based on images from multi-echo and double double echo 
sequences. Two liver biopsies were required for histologic analyses. The first was scheduled 
during the screening visit, unless participants had a liver biopsy available up to 6 months 
before screening. The second biopsy was taken upon study completion at week 48. Liver 
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biopsies were centrally read by a NASH Clinical Research Network pathologist for 
confirmation of the diagnosis of NASH and for assessment and grading of NAS (steatosis, 
lobular inflammation and ballooning) and stage of fibrosis (F0–F3). Serum ALT, serum C4 
and metabolic indicators (serum glucose and serum cholesterol) were also assessed at 
scheduled clinic visits. 
Treatment-emergent adverse events (TEAEs) were monitored at all study visits. Stool 
hardness was assessed by recording the softest evacuation during the 24 hours before each 
clinic visit using the Bristol Stool Chart. Stool frequency was assessed by the number of 
bowel movements during the 24 hours before each clinic visit, and a frequency of six or 
more bowel movements per day was deemed potentially clinically important. Vital signs, 
weight, waist-to-hip ratio, electrocardiogram and clinical laboratory tests (chemistry, 
haematology, coagulation and urinalysis) were also monitored at scheduled visits. 
Sample size calculation 
Sample size calculations were based on expected response rates of 21% in the placebo 
group and 45% in the active group in the primary efficacy outcome.37 To achieve 80% power 
with a 10% type I error, 67 participants per treatment group were required to complete the 
study. Owing to early termination, the study did not meet the target sample size. Therefore, 
all results are descriptive and non-inferential. 
Interim statistical analyses 
The safety set included all participants who were randomized, had taken at least one dose of 
volixibat or placebo and had at least one post-baseline safety assessment. The full analysis 
set included all participants in the safety set who had at least one post-baseline efficacy 
assessment. The interim analysis set included all participants in the safety set who had both 
baseline and scheduled week 24 efficacy assessment (MRI-PDFF and ALT) at the time of 
the interim analysis. The pharmacodynamic set included all participants who had provided at 
least one blood sample after receiving their first dose of volixibat or placebo. 
Dose-selection analyses were conducted at the interim analysis to determine which volixibat 
dose or doses were to be discontinued on the basis of efficacy, safety and tolerability. The 
probability of a clinically important effect on MRI-PDFF (≥5% absolute reduction) and on 
serum ALT (≥20% reduction) was calculated from the posterior distribution of Bayesian 
hierarchical models, which modelled changes in these outcomes across the three volixibat 
arms. Doses were not investigated further if the probability of a clinically important effect for 
both MRI-PDFF and ALT levels was less than or equal to 10%. Volixibat doses were to be 
discontinued on the basis of poor tolerability if six or more additional participants 
discontinued the study owing to any particular TEAE compared with the placebo group. If 
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volixibat doses were deemed unsafe on the basis of clinical judgement, then randomization 
to that dose was discontinued.  
Interim endpoints were stratified into subgroups of sex, presence of T2DM, baseline NAS 
and stage of fibrosis post hoc.   
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Results 
Participant disposition 
In total, 585 individuals were screened, and 197 participants were randomized to receive 
volixibat 5 mg (n = 49), volixibat 10 mg (n = 50), volixibat 20 mg (n = 49) or placebo (n = 49; 
Fig. 1). One participant in the volixibat 10 mg group was lost to follow-up before receiving 
treatment; therefore, 196 participants were included in the safety set. Eighty participants 
received at least 24 weeks of treatment with volixibat 5 mg (n = 21), volixibat 10 mg (n = 20), 
volixibat 20 mg (n = 18) or placebo (n = 21) and were included in the interim analysis. At the 
time of the interim analysis, 48 participants had completed the study and provided data to 
week 48, and 43 had paired liver biopsies at screening and at week 48 (volixibat 5 mg, n = 
11; volixibat 10 mg, n = 11; volixibat 20 mg, n = 8; placebo, n = 13). 
Following the interim analysis, the study was terminated owing to lack of efficacy. Of the 196 
participants who received a dose of volixibat or placebo, most (75.5%; n = 148) did not 
complete the study, mainly owing to termination of the study by the sponsor (60.7%) or to 
TEAEs (10.7%). The most common TEAE leading to study withdrawal was diarrhoea (7.1%). 
Demographic and baseline characteristics 
Demographic and baseline characteristics were generally well balanced between the 
treatment groups (Table 1). The 196 participants in the safety set had a mean age of 
53.1 years (standard deviation [SD] 12.78). Most participants were white (89.3%), were 
female (60.2%) and had a body mass index (BMI) in the obese range (73.5%), with a mean 
BMI of 34.5 kg/m2 (SD 6.35). Overall, 43.4% of participants had T2DM. 
At baseline, mean NAS was 5.2 points (SD 1.08), mean MRI-PDFF was 18.5% (SD 8.24), 
mean serum C4 level was 39.7 ng/mL (SD 35.56) and median serum ALT level was 49.5 
(interquartile range 42.5). Mean baseline NAS, MRI-PDFF and C4 levels and median ALT 
levels were similar across all treatment groups, as was the proportion of participants with 
ALT levels in the normal range (Table 1). Overall, 16.8% of participants had no fibrosis, 
38.3% had stage 1a–c fibrosis, 13.3% had stage 2 fibrosis and 31.1% had stage 3 fibrosis 
(0.5% of participants did not have baseline fibrosis data). 
Indicators of target engagement 
Mean serum C4 concentrations increased from baseline to week 24 by 38.5 ng/mL 
(SD 53.18) in participants receiving any dose of volixibat, with no change in the placebo 
group (–3.2 ng/mL [SD 26.05]). Mean increases in serum C4 concentrations did not appear 
to be dose-dependent, whereas mean decreases in serum total cholesterol, low-density 
lipoprotein (LDL) cholesterol and glucose concentrations were dose-dependent (Table 2). 
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Mean serum total cholesterol levels decreased from baseline to week 24 by 14.5 mg/dL 
(SD 28.32) in participants receiving any dose of volixibat and increased by 1.0 mg/dL 
(SD 24.64) in the placebo group. Mean serum LDL cholesterol levels decreased from 
baseline to week 24 by 16.1 mg/dL (SD 25.31) in participants receiving any dose of volixibat 
and decreased by 1.4 mg/dL (SD 18.97) in the placebo group. Mean serum cholesterol (total 
and LDL) and C4 levels returned to baseline by week 52 follow-up after treatment had 
stopped (Fig. S1). Mean change in serum glucose levels from baseline to week 24 was 
−3.0 mg/dL (SD 29.66) in participants receiving any dose of volixibat and +3.0 mg/dL (SD 
34.43) in the placebo group. 
Efficacy 
At week 24, no dose of volixibat had a probability of a clinically important effect above 10% 
in the Bayesian model (Table 3), leading to early termination of the study. 
MRI-PDFF 
Change from baseline in MRI-PDFF did not meet the predefined criteria for clinically 
significant efficacy (≥5% absolute decrease) in any of the volixibat dose groups at week 24 
(Table 3) or week 48 (Table S1). Mean absolute percentage changes from baseline to week 
24 in MRI-PDFF were similar at all doses of volixibat: 5 mg (–0.4% [SD 5.73]), 10 mg (–0.2% 
[SD 7.91]) or 20 mg (–1.3% [SD 4.85]) versus placebo (+0.2% [SD 5.11]). No improvements 
in MRI-PDFF at week 24 were observed at any dose of volixibat in post hoc subgroup 
analyses (sex, presence of T2DM, baseline NAS or stage of fibrosis). 
Serum ALT levels 
Change from baseline in serum ALT levels did not meet the predefined criteria for clinically 
significant efficacy (≥20% decrease) in any of the volixibat dose groups at week 24 (Table 3) 
or week 48 (Table S1). Mean absolute change from baseline to week 24 in serum ALT levels 
was not different for any dose of volixibat: 5 mg (+6.9 U/L [SD 29.87]), 10 mg (+7.3 U/L [SD 
42.90]) or 20 mg (–3.3 U/L [SD 26.20]) versus placebo (–6.3 U/L [SD 30.36]). Overall, 3.8% 
of participants (one participant per volixibat dose) had increases in ALT level greater than 
three times the ULN. No participants had an increase in ALT levels of greater than three 
times baseline. No improvement in serum ALT levels at week 24 was observed at any dose 
of volixibat in post hoc subgroup analyses (sex, presence of T2DM, baseline NAS or stage 
of fibrosis). 
Liver histology at week 48 
When the three histologic endpoints (≥2-point reduction in NAS without worsening fibrosis 
[primary efficacy endpoint], fibrosis reduction and NASH resolution without worsening 
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fibrosis) were assessed in participants who had liver biopsies at baseline and week 48 
(n = 43), response rates were generally higher in the placebo group than in the volixibat 
groups (Fig. 2). There were no notable changes in individual components of NAS at week 48 
(Table S1). The stage of fibrosis at week 48 is also shown in Table S1. 
In participants with a baseline fibrosis stage of 2 or higher (n = 23), response rates for each 
of the three histologic endpoints were generally higher in the placebo group (50.0–66.7%) 
than in the volixibat dose groups (16.7–66.7%) at week 48 (Fig. 2). In participants with a 
baseline NAS of 4 or more (n = 40), response rates for each of the three histologic endpoints 
were generally higher in the placebo group (33.3–41.7%) than in the volixibat dose groups 
(12.5–45.5%) at week 48. 
Safety and tolerability 
TEAEs were reported in 130/147 participants receiving volixibat (88.4%) and 37/49 
participants receiving placebo (75.5%) (Table 4). Serious TEAEs were reported in 3/147 
participants receiving volixibat (2.0%) and 1/49 participants receiving placebo (2.0%); all 
serious TEAEs were unrelated to volixibat, and no TEAEs resulted in death. Most TEAEs 
were mild or moderate in severity. Severe TEAEs were reported in 9/147 participants 
receiving volixibat (6.1%) and 2/49 participants receiving placebo (4.1%); the incidence of 
severe TEAEs was similar across the volixibat doses. TEAEs leading to discontinuation of 
treatment were reported in 20/147 participants receiving volixibat (13.6%) and 1/49 
participants receiving placebo (2.0%). 
Diarrhoea was the most common TEAE, occurring in a non-dose-dependent manner in 
108/147 participants receiving volixibat (73.5%) and in 10/49 participants receiving placebo 
(20.4%). Diarrhoea was also the most common TEAE leading to discontinuation of 
treatment, occurring in a non-dose-dependent manner in 14/147 participants receiving 
volixibat (9.5%) and in no participants receiving placebo. Most diarrhoea occurred 
intermittently. Across the safety set, 86/196 participants (43.9%) had intermittent TEAEs of 
diarrhoea, and 41/196 participants (20.9%) had continuous TEAEs of diarrhoea (Fig. S2). 
Most diarrhoea TEAEs that led to discontinuation of volixibat (12/14 events) occurred in the 
first 2 weeks of treatment. The incidence of diarrhoea TEAEs decreased after week 2 (Fig. 
S3). Other common gastrointestinal TEAEs in participants receiving volixibat included 
abdominal pain (25/147; 17.0%), nausea (16/147; 10.9%) and vomiting (8/147; 5.4%), which 
occurred at slightly lower or similar rates in the placebo group. 
Based on the Bristol Stool Chart, stools were softer during treatment with volixibat than with 
placebo. Most stools were classified as normal softness at the week 52 follow-up, once 
treatment had stopped (Table S2). Bowel movements were more frequent with volixibat than 
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with placebo at week 2 but not at subsequent time points (Table S3). Changes in stool 
softness and bowel movement frequency were not dose-dependent. 
There were no clear trends over time, or differences between treatment groups, in vital 
signs, physical findings (including waist-to-hip ratio), or electrocardiogram or laboratory data. 
There was a slight decrease in body weight in both the placebo and volixibat groups (mean 
change from baseline to week 24: placebo = −0.2 kg [SD 3.49]; volixibat = −1.4 kg [SD 
3.90]).   
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Discussion 
The ASBT inhibitor volixibat increased mean serum C4 and decreased serum total 
cholesterol levels, indicating target engagement, but it had no effect on steatosis, serum ALT 
levels or liver histology in adults with NASH in this randomized, double-blind, phase 2, 
placebo-controlled, dose-finding study. 
Based on previous clinical and preclinical studies, volixibat was hypothesized to exert 
therapeutic effects in patients with NASH by blocking enterohepatic recirculation of BAs via 
inhibition of ASBT, thereby stimulating de novo production of BAs from cholesterol that is 
present in the liver and the bloodstream. The resulting reductions in systemic and hepatic 
cholesterol levels may then have anti-inflammatory, anti-steatotic and anti-fibrotic effects.21-32 
In this study, volixibat increased serum C4 concentrations and decreased serum cholesterol, 
indicating that BA synthesis from cholesterol was upregulated as a consequence of 
adequate target engagement. 
Upregulation of BA synthesis and decreased serum cholesterol levels were not, however, 
accompanied by any clinically significant reduction in steatosis or serum ALT levels after 
24 weeks of treatment. There was also no improvement in any liver histology outcome after 
48 weeks of treatment, based on the subset of participants who had completed the study. 
The elevated serum C4 and decreased total and LDL cholesterol levels observed in this 
study are consistent with results from a phase 1 study in healthy volunteers.27 Although 
these results suggest that inhibition of ASBT with volixibat monotherapy may increase BA 
synthesis from cholesterol, there does not appear to be any concomitant effect in reducing 
hepatic steatosis or injury, despite evidence for a mechanistic link in mouse models.30,31 In 
mice that were fed a high-fat diet, statistically significant reductions in hepatocellular 
hypertrophy and NAS were accompanied by attenuated serum cholesterol levels, changes in 
BA metabolism and a trend towards a small decrease in steatosis following administration of 
volixibat.31 Animal models may not accurately reflect the pathophysiology of NASH in 
humans. There is a possibility that the dose of volixibat or the duration of treatment was 
insufficient to mediate effects on steatosis in this study. However, the lack of consistent 
dose-dependent relationships in indicators of target engagement or efficacy outcomes 
suggests that an increased dose of volixibat might not have led to any greater target 
engagement. Similarly, after immediate improvement, serum cholesterol and C4 levels 
remained consistent throughout the study duration, indicating that participants would not 
have benefited from additional duration of treatment. 
The safety profile of volixibat in the present study was consistent with that seen in phase 1 
trials in healthy volunteers, and in overweight and obese adults.18,26,27 There was a mild 
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increase in serum ALT levels in all the volixibat groups compared with the placebo group, as 
reported in a phase 1 trial.27 These elevated ALT levels were asymptomatic and were not 
dose-dependent in either the phase 1 trial or the current study. Elevated ALT levels may 
result from increased hepatic cholesterol turnover38 and represent a transient and expected 
benign side effect of volixibat treatment. Most TEAEs were mild or moderate in severity, and 
serious TEAEs were reported at the same rate in the volixibat and placebo groups. No 
TEAEs had a fatal outcome. The most frequent TEAE in participants receiving volixibat was 
diarrhoea. Diarrhoea TEAEs result from increased BA concentrations in the colon, which 
stimulate colon motility and secretion of mucus and water, decreasing colonic transit 
time.39,40 Prevalence of diarrhoea was not dose-dependent, and the incidence decreased 
after week 2. Intermittent diarrhoea was observed more frequently than persistent diarrhoea. 
Diarrhoea TEAEs were observed at similar or higher rates to those reported in phase 1 
studies, although it should be noted that the longest treatment time in these studies was 
28 days.18,26,27 
Strengths of the present study include the predefined interim analysis, with application of a 
Bayesian stopping rule to determine dose selection, and the use of appropriate efficacy 
outcomes. In particular, the MRI-PDFF method used to assess steatosis has been shown to 
be more sensitive than histology in quantifying change in liver fat in patients with NASH.41 
However, it should be noted that, although the non-invasive efficacy endpoints of MRI-PDFF 
and serum ALT levels give an indication of steatosis, they may not fully capture the 
additional NASH components of inflammation and ballooning. The study was powered for 
the primary efficacy outcome of a 48-week reduction in NAS of at least 2 points from 
baseline without worsening fibrosis in liver biopsies. Early termination of the study, based on 
non-invasive efficacy assessments, prevented the target histologic sample size from being 
met. Post hoc evaluation of the primary efficacy outcome after termination was limited by the 
small numbers of participants who completed 48 weeks of treatment (n = 8–11 per group). 
By the time the study was terminated owing to lack of efficacy in non-invasive assessments, 
43 participants had already undergone invasive and unnecessary liver biopsies. This may be 
considered a limitation of the study that exposed participants to potential harm. The inclusion 
of endpoints assessing BA profiles and microbiota may have also been a valuable addition 
to this study, potentially providing further insight into the metabolic effects of volixibat.  
In conclusion, this phase 2 study did not reveal any beneficial effects of volixibat on steatosis 
or ALT levels after 24 weeks of treatment. The increased C4 levels do indicate that inhibiting 
ASBT-mediated BA reuptake with volixibat leads to an increase in hepatic BA synthesis, in 
accordance with the hypothesized mechanism of action. The lack of effect on liver health, in 
conjunction with adequate target engagement, suggests that ASBT inhibition is unlikely to be 
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an effective treatment for patients with NASH, but offers promise for the development of 
ASBT inhibitors in alternative therapy areas.  
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Figures and tables 
 
Tables 
Table 1. Baseline demographic and disease characteristics. 
  
 Volixibat  
  
Placebo 5 mg 10 mg 20 mg All 
doses 
Total 
Safety set n = 49 n = 49 n = 49 n = 49 n = 147 n = 196 
Age, years, mean (SD)  53.4 
(11.75) 
52.8 
(14.13) 
53.0 
(11.84) 
53.2 
(13.61) 
53.0 
(13.14) 
53.1 
(12.78) 
Sex, n (%)       
 Male 17 
(34.7) 
22 
(44.9) 
15 
(30.6) 
24 
(49.0) 
61 
(41.5) 
78 
(39.8) 
 Female 32 
(65.3) 
27 
(55.1) 
34 
(69.4) 
25 
(51.0) 
86 
(58.5) 
118 
(60.2) 
Ethnicity, n (%)       
 Hispanic or Latino  7 
(14.3) 
9 
(18.4) 
10 
(20.4) 
7 
(14.3) 
26 
(17.7) 
33 
(16.8) 
 Not Hispanic or Latino  42 
(85.7) 
40 
(81.6) 
39 
(79.6) 
42 
(85.7) 
121 
(82.3) 
163 
(83.2) 
Race, n (%)       
 White 41 
(83.7) 
46 
(93.9) 
47 
(95.9) 
41 
(83.7) 
134 
(91.2) 
175 
(89.3) 
 Non-white 8 
(16.3) 
3 
(6.1) 
2 
(4.1) 
8 
(16.3) 
13 
(8.8) 
21 
(10.7) 
 Black or African American  4 
(8.2) 
0 
 
1 
(2.0) 
4 
(8.2) 
5 
(3.4) 
9 
(4.6) 
 Asian  4 
(8.2) 
2 
(4.1) 
1 
(2.0) 
4 
(8.2) 
7 
(4.8) 
11 
(5.6) 
 Multiple  0 1 
(2.0) 
0 0 1 
(0.7) 
1 
(0.5) 
T2DM, n (%)       
 Yes 21 
(42.9) 
22  
(44.9) 
21  
(42.9) 
21  
(42.9) 
64  
(43.5) 
85  
(43.4) 
 No 28 
(57.1) 
27  
(55.1) 
28  
(57.1) 
28  
(57.1) 
83  
(56.5) 
111 
(56.6) 
NAS, mean (SD) 5.2 
(0.96) 
5.2 
(1.01) 
5.2 
(1.26) 
5.1 
(1.11) 
5.1 
(1.12) 
5.2 
(1.08) 
Stage of fibrosis, n (%)       
 0: none 11 
(22.4) 
7 
(14.3) 
7 
(14.3) 
8 
(16.3) 
22  
(15.0) 
33  
(16.8) 
 1a: mild zone 3 
perisinusoidal (requires 
trichome) 
12 
(24.5) 
13  
(26.5) 
8 
(16.3) 
9 
(18.4) 
30  
(20.4) 
42  
(21.4) 
 1b: moderate zone 3 
perisinusoidal (visible on 
haematoxylin and eosin 
staining) 
7 
(14.3) 
7 
(14.3) 
7 
(14.3) 
6 
(12.2) 
20  
(13.6) 
27  
(13.8) 
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 Volixibat  
  
Placebo 5 mg 10 mg 20 mg All 
doses 
Total 
Safety set n = 49 n = 49 n = 49 n = 49 n = 147 n = 196 
 1c: portal/periportal only 0 3 
(6.1) 
2 
(4.1) 
1 
(2.0) 
6 
(4.1) 
6 
(3.1) 
 2: portal, periportal and 
perisinusoidal 
7 
(14.3) 
6 
(12.2) 
6 
(12.2) 
7 
(14.3) 
19  
(12.9) 
26  
(13.3) 
 3: bridging 12 
(24.5) 
13  
(26.5) 
18  
(36.7) 
18  
(36.7) 
49  
(33.3) 
61  
(31.1) 
 4: cirrhosis 0 0 0 0 0 0 
 Missing  0 0 1  
(2.0) 
0 1  
(0.7) 
1  
(0.5) 
Stage of fibrosis, mean (SD)a 1.4 
(1.10) 
1.5 
(1.04) 
1.7 
(1.12) 
1.7 
(1.14) 
1.6 
(1.10) 
1.6 
(1.10) 
Stage of fibrosis, mediana 1 1 1 2 1 1 
MRI-PDFF, %, mean (SD) 18.8 
(8.78) 
20.4 
(7.60) 
17.8 
(8.72) 
17.0 
(7.66) 
18.4 
(8.08) 
18.5 
(8.24) 
Interim analysis set n = 21 n = 21 n = 20 n = 18 n = 59 n = 80 
Serum ALT, U/L, median (IQR) 43.0 
(36.0) 
60.0 
(48.0) 
58.5 
(50.5) 
50.0 
(32.0) 
53.0 
(47.0) 
49.5 
(42.5) 
ALT levels within normal range, 
n (%)b 
13  
(61.9) 
10  
(47.6) 
10 
(50.0) 
11 
(61.1) 
31 
(52.5) 
44 
(55.0) 
Pharmacodynamic set n = 49 n = 49 n = 47 n = 49 n = 145 n = 194 
Serum C4, ng/mL, mean (SD) 42.9 
(33.19) 
39.9 
(29.73) 
39.2 
(36.36) 
37.0 
(42.86) 
38.7 
(36.37) 
39.7 
(35.56) 
Percentages may not sum to 100 owing to rounding error. aWhen computing mean/median stage of 
fibrosis, stages 1a, 1b and 1c were all taken as 1. bNormal range of ALT: 0–55 U/L. 
ALT, alanine aminotransferase; C4, 7-alpha-hydroxy-4-cholesten-3-one; IQR, interquartile range; 
MRI-PDFF, magnetic resonance imaging-proton density fat fraction; NAS, non-alcoholic fatty liver 
disease activity score; SD, standard deviation; T2DM, type 2 diabetes mellitus.  
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Table 2. Mean (SD) change from baseline to week 24 in serum C4 levels 
(pharmacodynamic set; N = 194) and in metabolic indicators (safety set; N = 196). 
C4, 7-alpha-hydroxy-4-cholesten-3-one; LDL, low-density lipoprotein; SD, standard deviation. 
  
   
Volixibat 
 
 Placebo 5 mg 10 mg 20 mg All doses 
Serum C4, 
ng/mL 
n 34 34 31 29 94 
 
−3.2 
(26.05) 
32.8 
(40.26) 
53.7 
(48.30) 
28.8 
(67.75) 
38.5 
(53.18) 
Serum glucose, 
mg/dL 
n 37 37 33 33 103 
 
3.0  
(34.43) 
−0.5  
(28.64) 
−3.7  
(33.86) 
−5.1  
(26.87) 
−3.0  
(29.66) 
Serum 
cholesterol, 
mg/dL 
n 37 37 33 33 103 
 
1.0  
(24.64) 
−9.0  
(20.17) 
−12.7 
(30.85) 
−22.5 
(32.29) 
−14.5 
(28.32) 
Serum LDL 
cholesterol, 
mg/dL 
n 37 37 33 33 103 
 
−1.4  
(18.97) 
−11.4 
(21.09) 
−15.0 
(26.90) 
−22.5 
(27.36) 
−16.1 
(25.31) 
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Table 3. Dose-selection analyses and changes from baseline to week 24 in MRI-PDFF 
and serum ALT levels (interim analysis set; N = 80). 
 
  
 Volixibat 
  
Placebo 
(n = 21) 
5 mg 
(n = 21) 
10 mg 
(n = 20) 
20 mg 
(n = 18) 
Dose selection (Bayesian model) 
Absolute percentage change in MRI-PDFF    
 Mean (95% CI)  −0.6 
(−2.3, 1.2) 
−0.6 
(−2.3, 1.3) 
−0.7 
(−2.6, 1.1) 
 Futility threshold  −3.8 −3.8 −3.8 
 PCIE, %  0.0 0.0 0.0 
Percentage change in ALT    
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ALT, alanine aminotransferase; CI, confidence interval; MRI-PDFF, magnetic resonance imaging-
proton density fat fraction; PCIE, probability of a clinically important effect; SD, standard deviation. 
  
 Mean (95% CI)  11.8 
(−1.2, 24.5) 
11.4 
(−1.5, 23.8) 
10.1 
(−3.8, 22.4) 
 Futility threshold  −11.3 −11.4 −11.0 
 PCIE, %  0.0 0.0 0.1 
Interim efficacy analysis  
Absolute percentage change in MRI-PDFF     
 Mean (SD) 0.2 (5.11) −0.4 (5.73) −0.2 (7.91) −1.3 (4.85) 
Relative percentage change in ALT    
 Mean (SD) −0.0 (25.60) 17.1 (48.72) 14.1 (45.13) 2.4 (39.02) 
Absolute change in ALT, U/L     
 Mean (SD) −6.3  
(30.36) 
6.9  
(29.87) 
7.3  
(42.90) 
−3.3  
(26.20) 
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Table 4. TEAEs by treatment group (safety set; N = 196). 
  
 Volixibat 
  
Placebo 
(n = 49), 
n (%) 
m 
5 mg  
(n = 49), 
n (%) 
m 
10 mg 
(n = 49), 
n (%) 
m 
20 mg 
(n = 49), 
n (%) 
m 
All doses 
(n = 147), 
n (%) 
m 
Any TEAE 37 (75.5) 
130 
44 (89.8) 
151 
44 (89.8) 
171 
42 (85.7) 
190 
130 
(88.4) 
512 
 Serious TEAE 1 (2.0) 
3 
1 (2.0) 
1 
2 (4.1) 
2 
0 3 (2.0) 
3 
 Severe TEAE 2 (4.1) 
4 
1 (2.0) 
1 
4 (8.2) 
6 
4 (8.2) 
6 
9 (6.1) 
13 
TEAE related to IP 15 (30.6) 
29 
40 (81.6) 
69 
36 (73.5) 
68 
35 (71.4) 
74 
111 
(75.5) 
211 
 Serious TEAE related to 
IP 
0 0 0 0 0 
 Severe TEAE related to 
IP 
1 (2.0) 
1 
0 2 (4.1) 
2 
4 (8.2) 
5 
6 (4.1) 
7 
TEAEs leading to death  0 0 0 0 0 
TEAEs leading to IP 
withdrawal/discontinuation 
1 (2.0)  
1 
9 (18.4)  
9 
3 (6.1)  
3 
8 (16.3)  
8 
20 (13.6) 
20 
Most common TEAEsa       
 Diarrhoea 10 (20.4) 
11 
38 (77.6) 
43 
35 (71.4) 
46 
35 (71.4) 
47 
108 
(73.5) 
136 
 Abdominal pain 3 (6.1) 
3 
10 (20.4) 
11 
9 (18.4) 
10 
6 (12.2) 
6 
25 (17.0) 
27 
 Nausea 2 (4.1) 
2 
5 (10.2) 
6 
4 (8.2) 
6 
7 (14.3) 
7 
16 (10.9) 
19 
 Fatigue 2 (4.1) 
2 
3 (6.1) 
4 
3 (6.1) 
3 
3 (6.1) 
3 
9 (6.1) 
10 
 Urinary tract infection 1 (2.0) 
1 
1 (2.0) 
2 
7 (14.3) 
8 
1 (2.0) 
1 
9 (6.1) 
11 
 Vomiting  3 (6.1) 
3 
1 (2.0) 
1 
3 (6.1) 
4 
4 (8.2) 
4 
8 (5.4) 
9 
aTEAEs occurring in at least 5% of the volixibat all doses group.  
IP, investigational product; m, number of events; n, number of participants experiencing the event; 
TEAE, treatment-emergent adverse event.  
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Figure legends 
 
Fig. 1. Participant disposition. 
aThe safety set included 196 participants because one of the 197 participants who were 
randomized to the volixibat 10 mg group was lost to follow-up before receiving treatment. 
 
Fig. 2. Proportion of participants in the overall sample and of participants with 
baseline fibrosis score of at least 2 with: at least a 2-point reduction in NAS without 
worsening fibrosis; fibrosis reduction; and NASH resolution without worsening 
fibrosis.  
NAS, non-alcoholic fatty liver disease activity score; NASH, non-alcoholic steatohepatitis. 
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Figures 
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Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis results 
from a randomized, phase 2 study 
 
Highlights 
• Volixibat decreased serum C4 (bile acid synthesis biomarker) and cholesterol. 
• These results suggest adequate target engagement. 
• Volixibat had no therapeutic impact on steatosis or liver injury in NASH. 
• Treatment-emergent adverse events were mainly of mild or moderate grade. 
• No serious adverse events were attributed to volixibat. 
